ReviewMediators of inflammation2015
Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases.
Review in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Interleukin-17 in Health and Disease: Special Focus on Its Role in Autoimmune Hepatitis.Cells · 2026Review
- cPLACytotechnology · 2025Article
- Bile acids and their receptors in hepatic immunity.Liver research (Beijing, China) · 2025Review
- Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective.Frontiers in cellular and infection microbiology · 2025Review
- Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Comparative Transcriptomic Analysis Reveals the Immunosuppressive Targets of Mesalazine in Dextran Sulfate Sodium-Induced Ulcerative Colitis.Frontiers in genetics · 2021Article
- The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis.Annals of translational medicine · 2019Article
- Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis.Frontiers in pediatrics · 2019Review
- γδ T cells in liver diseases.Frontiers of medicine · 2018Review
- Bone marrow derived-mesenchymal stem cells downregulate IL17A dependent IL6/STAT3 signaling pathway in CCl4-induced rat liver fibrosis.PloS one · 2018Article
- Serum Levels of IL-33 and Correlation with IL-4, IL-17A, and Hypergammaglobulinemia in Patients with Autoimmune Hepatitis.Mediators of inflammation · 2018Article
- Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.Frontiers in oncology · 2018Review
- Liver Illness and Psoriatic Patients.BioMed research international · 2018Review
- The Immunogenetics of Autoimmune Cholestasis.Clinics in liver disease · 2016Review
- Th1 and Th17 Cells in Tuberculosis: Protection, Pathology, and Biomarkers.Mediators of inflammation · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence reveals that various cytokines and tissue microenvironments contribute to liver inflammation and autoimmunity, and IL-17 family is one of highlights acknowledged. Although the implication of IL-17 family in most common autoimmune diseases (such as psoriasis, inflammatory bowel disease, and rheumatoid arthritis) has been extensively characterized, the role of this critical family in pathophysiology of autoimmune liver diseases (AILD) still needs to be clarified. In the review, we look into the intriguing biology of IL-17 family and further dissect on the intricate role of IL-17-mediated pathway in AILD. Considering encouraging data from preclinical and clinical trials, IL-17 targeted therapy has shown promises in several certain autoimmune conditions. However, blocking IL-17-mediated pathway is just beginning, and more fully investigation and reflection are required. Taking together, targeting IL-17-mediated responses may open up new areas of potential clinical treatment for AILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.